Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 6Hematologic Neoplasms 5Breast Neoplasms 4Urinary Bladder Neoplasms 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Lung Neoplasms 3Leukemia, Myeloid, Acute 3Glioma 3Colorectal Neoplasms 3Prostatic Neoplasms 2Neoplasms by Site 2Motor Activity 2Head and Neck Neoplasms 2Glioblastoma 2Carcinoma, Transitional Cell 2Anxiety Disorders 2Anatomic Stage I Breast Cancer AJCC v8 2Uveal Melanoma 1Uterine Neoplasms 1Urologic Neoplasms 1Urologic Diseases 1Urogenital Neoplasms 1Urinary Bladder Diseases 1Urethral Neoplasms 1Ureteral Neoplasms 1Stomatitis 1Stomach Neoplasms 1Smoking Cessation 1Small Cell Lung Carcinoma 1

Interventions

Gemcitabine 2rucaparib 1romidepsin 1pembrolizumab 1enfortumab vedotin 1Trastuzumab 1Standard of Care 1Sorafenib 1Paclitaxel 1Depsipeptides 1Crizotinib 1Cisplatin 1Carboplatin 1Afatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Urethral Neoplasms × Standard of Care × Clear all
NCT01353222 2017-05-25

DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma

Dendreon

Phase 2 Terminated
142 enrolled 13 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡